Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHAKER R DAKHIL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1417918079
CMS profile
199929
Location
WICHITA, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$112,607.50

300 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
US Oncology Corporate, Inc. $60,069.93 3
Daiichi Sankyo Inc. $13,476.39 16
Astellas Pharma US Inc $9,969.59 9
AstraZeneca Pharmaceuticals LP $4,406.64 12
Fresenius Kabi USA, LLC $3,150.00 1
Takeda Pharmaceuticals U.S.A., Inc. $2,503.18 8
Amgen Inc. $2,156.11 14
BeiGene, Ltd. $1,950.00 1
MorphoSys, US Inc. $1,822.01 2
Kite Pharma, Inc. $1,742.44 6
Aveo Pharmaceuticals, Inc. $1,513.92 2
Seagen Inc. $1,405.70 16
PFIZER INC. $1,362.26 10
Coherus Biosciences Inc. $1,350.00 1
Bayer HealthCare Pharmaceuticals Inc. $1,116.71 12
Janssen Scientific Affairs, LLC $1,010.00 1
Karyopharm Therapeutics Inc. $791.78 3
Novartis Pharmaceuticals Corporation $338.18 24
Epizyme, Inc., $204.54 7
E.R. Squibb & Sons, L.L.C. $171.28 15
PUMA BIOTECHNOLOGY, INC. $156.98 4
Merck Sharp & Dohme Corporation $149.36 11
GENZYME CORPORATION $144.99 10
Blueprint Medicines Corporation $138.42 7
Genentech USA, Inc. $128.85 11
Eisai Inc. $83.93 5
Regeneron Healthcare Solutions, Inc. $81.37 5
EMD Serono, Inc. $76.47 4
TerSera Therapeutics LLC $74.89 4
GlaxoSmithKline, LLC. $69.29 5
BeiGene USA, Inc. $68.20 8
Janssen Biotech, Inc. $67.72 5
Gilead Sciences, Inc. $65.63 5
Foundation Medicine, Inc. $60.56 3
AbbVie Inc. $60.15 4
Pharmacyclics LLC, An AbbVie Company $56.11 4
Incyte Corporation $46.30 3
Exelixis Inc. $41.94 3
Ipsen Biopharmaceuticals, Inc $41.47 2
Acrotech Biopharma LLC $41.32 3
Mylan Institutional Inc. $36.33 2
Boehringer Ingelheim Pharmaceuticals, Inc. $35.85 2
Blue Earth Diagnostics Limited $35.59 2
Celgene Corporation $31.58 2
Heron Therapeutics, Inc. $30.65 2
Kyowa Kirin, Inc. $27.92 2
Dendreon Pharmaceuticals LLC $27.78 2
Rigel Pharmaceuticals, Inc. $26.02 2
AMAG Pharmaceuticals, Inc. $24.50 2
Taiho Oncology, Inc. $22.62 2
ARRAY BIOPHARMA INC $20.39 2
Servier Pharmaceuticals LLC $16.68 1
Myriad Genetic Laboratories, Inc. $15.97 1
SUN PHARMACEUTICAL INDUSTRIES INC. $15.37 1
Global Blood Therapeutics, Inc. $13.98 1
SANOFI-AVENTIS U.S. LLC $13.81 1
ARBOR PHARMACEUTICALS, INC. $12.67 1
Agios Pharmaceuticals, Inc. $12.01 1
Acceleron Pharma, Inc. $11.97 1
Dova Pharmaceuticals $11.20 1

Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHAKER R DAKHIL

NPI 1417918079 · CMS profile ID 199929

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

WICHITA, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417918079?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHAKER R DAKHIL, NPI 1417918079, CMS profile ID 199929. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417918079?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SHAKER R DAKHIL, NPI 1417918079, CMS profile ID 199929. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417918079?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SHAKER R DAKHIL, NPI 1417918079, CMS profile ID 199929, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1417918079?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

300 matching records · $112,607.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 300 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 300.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $8.9610/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819904571 CMS
Genentech USA, Inc. $13.8310/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835976353 CMS
Seagen Inc. $8.3710/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832176365 CMS
Coherus Biosciences Inc. $1,350.0010/14/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855103569 CMS
Daiichi Sankyo Inc. $6,850.0010/12/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836325539 CMS
E.R. Squibb & Sons, L.L.C. $14.7810/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783506727 CMS
Exelixis Inc. $12.4310/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838872551 CMS
PFIZER INC. $9.1710/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832985759 CMS
Bayer HealthCare Pharmaceuticals Inc. $8.3410/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789172515 CMS
Amgen Inc. $21.9810/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825781679 CMS
Amgen Inc. $9.5510/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826432545 CMS
AstraZeneca Pharmaceuticals LP $12.3210/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829857345 CMS
Mylan Institutional Inc. $18.4110/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965336287 CMS
Novartis Pharmaceuticals Corporation $22.4010/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812649791 CMS
PFIZER INC. $13.3710/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832939689 CMS
TerSera Therapeutics LLC $21.5010/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851046071 CMS
Astellas Pharma US Inc $9,855.0009/30/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821293923 CMS
E.R. Squibb & Sons, L.L.C. $14.4309/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783506729 CMS
Aveo Pharmaceuticals, Inc. $1,500.0009/28/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852623873 CMS
Pharmacyclics LLC, An AbbVie Company $14.9609/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781009301 CMS
Epizyme, Inc., $16.6109/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832339027 CMS
Epizyme, Inc., $5.4009/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832339031 CMS
Merck Sharp & Dohme Corporation $8.5809/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848516993 CMS
Merck Sharp & Dohme Corporation $10.8709/27/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848624111 CMS
Eisai Inc. $16.8609/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817999479 CMS
Novartis Pharmaceuticals Corporation $10.7309/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812649787 CMS
Bayer HealthCare Pharmaceuticals Inc. $1,000.0009/23/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789065221 CMS
Gilead Sciences, Inc. $14.6609/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848182307 CMS
Regeneron Healthcare Solutions, Inc. $18.9309/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809570879 CMS
Bayer HealthCare Pharmaceuticals Inc. $10.6109/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789042567 CMS
Heron Therapeutics, Inc. $13.5709/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781453695 CMS
Seagen Inc. $14.3309/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832176329 CMS
Novartis Pharmaceuticals Corporation $7.3809/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812649789 CMS
PFIZER INC. $19.0809/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832933109 CMS
Acrotech Biopharma LLC $12.1209/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855379189 CMS
PUMA BIOTECHNOLOGY, INC. $8.0909/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834090507 CMS
Genentech USA, Inc. $16.2909/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835976365 CMS
Janssen Biotech, Inc. $13.9709/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788216155 CMS
Daiichi Sankyo Inc. $1,712.5009/14/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836303645 CMS
E.R. Squibb & Sons, L.L.C. $5.4609/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783506713 CMS
Novartis Pharmaceuticals Corporation $14.2409/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812649785 CMS
US Oncology Corporate, Inc. $30,000.0009/13/2021 Charitable Contribution No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 823426371 CMS
Taiho Oncology, Inc. $11.2009/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843376651 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,372.5009/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819904569 CMS
Novartis Pharmaceuticals Corporation $19.3809/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812649783 CMS
Seagen Inc. $13.9009/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832176321 CMS
Daiichi Sankyo Inc. $685.0009/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836303611 CMS
GlaxoSmithKline, LLC. $17.4709/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802377187 CMS
BeiGene USA, Inc. $8.9709/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846698451 CMS
Blueprint Medicines Corporation $9.2509/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848929399 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $105,533.44 397
PY2020 $126,175.44 305
PY2021 $112,607.50 300
PY2022 $65,788.97 314
PY2023 $86,428.76 313
PY2024 $42,832.78 286
PY2025 $39,872.52 242

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $469.66 2
PY2025 Principal investigator $1,587,717.72 52
PY2024 Principal investigator $1,520,759.10 52
PY2023 Principal investigator $633,759.48 103
PY2022 Principal investigator $664,292.24 79
PY2021 Principal investigator $1,279,119.78 115
PY2020 Recipient $898.50 2
PY2020 Principal investigator $2,529,101.57 167
PY2019 Recipient $79,430.00 5
PY2019 Principal investigator $2,445,340.11 126

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $5,222.39 12/31/2025 Non-covered Recipient Entity
Cancer Center of Kansas
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab MK-3475 Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy KEYNOTE 975 No dispute reported 06/30/2026 1232927907
Principal investigator 1 Amgen Inc. $3,500.00 12/23/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) No dispute reported 06/30/2026 1246639891
Principal investigator 1 BeOne Medicines Ltd. $5,639.00 12/23/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190332177
Principal investigator 1 BeOne Medicines Ltd. $2,025.00 12/09/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190332179
Recipient Novartis Pharmaceuticals Corporation $332.54 12/07/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291284
Principal investigator 1 Amgen Inc. $38,476.00 11/25/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) No dispute reported 06/30/2026 1246649890
Principal investigator 1 BeOne Medicines Ltd. $1,282.00 11/12/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190332283
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,395.56 11/11/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190298334
Principal investigator 1 Incyte Corporation $23,619.09 11/10/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240512131
Principal investigator 1 Novartis Pharmaceuticals Corporation $214.02 10/28/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190298325
Principal investigator 1 Novartis Pharmaceuticals Corporation $151,514.98 10/27/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190298311
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $411.00 10/23/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS P.A.
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737859
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $248.00 10/23/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS P.A.
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737861
Principal investigator 1 Amgen Inc. $95,594.72 09/24/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS, HERITAGE PLAZA MEDICAL BUILDING
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) No dispute reported 06/30/2026 1246639889
Principal investigator 1 PFIZER INC. $1,519.00 09/02/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228757713
Principal investigator 1 BeOne Medicines Ltd. $2,806.00 08/26/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190332279
Principal investigator 1 BeOne Medicines Ltd. $2,025.00 08/12/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190332175
Recipient Novartis Pharmaceuticals Corporation $137.12 08/05/2025 Covered Recipient Physician CABL001AUS08 No dispute reported 06/30/2026 1190293488
Principal investigator 1 BeOne Medicines Ltd. $3,769.00 07/22/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190332281
Principal investigator 1 Incyte Corporation $22.05 06/24/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240512118
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $967.40 06/13/2025 Non-covered Recipient Entity
Cancer Center Of Kansas
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies No dispute reported 06/30/2026 1235998430
Principal investigator 1 Genentech, Inc. $1,750.05 06/09/2025 Non-covered Recipient Entity
MAYO CLINIC ROCHESTER REMIT PROCESSING
Chemo trastuzumab vs chemo trastuzumab pertuzumab No dispute reported 06/30/2026 1211622922
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,515.48 06/05/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS PA
A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184204155
Principal investigator 1 BeiGene, Ltd. $2,499.00 05/20/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322622
Principal investigator 1 BeiGene, Ltd. $3,399.00 05/12/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325110
Principal investigator 1 PFIZER INC. $1,519.00 05/05/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228772190
Principal investigator 1 BeiGene, Ltd. $1,552.00 04/29/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325112
Principal investigator 1 BeiGene, Ltd. $2,025.00 04/29/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325114
Principal investigator 1 Mirati Therapeutics, Inc. $4,560.72 04/28/2025 Non-covered Recipient Entity
Cancer Center Of Kansas
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther No dispute reported 06/30/2026 1236531209
Principal investigator 1 Merck Sharp & Dohme LLC $13,490.40 04/16/2025 Non-covered Recipient Entity
Cancer Center of Kansas
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab MK-3475 Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy KEYNOTE 975 No dispute reported 06/30/2026 1232927905
Principal investigator 1 Incyte Corporation $3,889.06 04/15/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240512123
Principal investigator 1 Hoffmann-La Roche Limited $16,515.50 04/10/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS PA
A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY No dispute reported 06/30/2026 1211583211
Principal investigator 1 BeiGene, Ltd. $1,716.00 04/08/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322620
Principal investigator 1 AstraZeneca UK Limited $8,341.43 04/02/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS, PA
A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1185543638
Principal investigator 1 Novartis Pharmaceuticals Corporation $355,996.06 04/02/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190298330
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,921.00 03/27/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
Two arm Randomized Phase 3 study in high risk NSCLC comparing canakinumab vs placebo in Adjuvant Setting No dispute reported 06/30/2026 1190298319
Principal investigator 1 BeiGene, Ltd. $4,214.00 03/25/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322618
Principal investigator 1 Acerta Pharma LLC $848.20 03/19/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS, PA
a randomized,multicenter,open label,3 arm phase 3 study of obinutuzumab in combination with chlorambucil,ACP 196 in combination with obinutuzumaband ACP 196 monotherapy in subjects with previously untreated chronic lymphocytic leukemia No dispute reported 06/30/2026 1185543634
Principal investigator 1 Acerta Pharma LLC $4,609.09 03/13/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS, PA
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1185543632
Principal investigator 1 Hoffmann-La Roche Limited $13,395.60 03/13/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS PA
A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY No dispute reported 06/30/2026 1211583208
Principal investigator 1 ABBVIE INC. $13,000.00 03/07/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS P A
M22-128 - A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) No dispute reported 06/30/2026 1202461402
Principal investigator 1 BeiGene, Ltd. $1,918.00 02/25/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322616
Principal investigator 1 PFIZER INC. $1,519.00 02/24/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228787799
Principal investigator 1 BeiGene, Ltd. $13,038.00 02/11/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322786
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,916.00 02/11/2025 Non-covered Recipient Entity
Translational Oncology Research International
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9ER No dispute reported 06/30/2026 1235992897
Principal investigator 1 BeiGene, Ltd. $1,439.81 02/03/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325314
Principal investigator 1 Incyte Corporation $44.10 01/30/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240512113
Principal investigator 1 BeiGene, Ltd. $2,025.00 01/28/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190320282
Principal investigator 1 BeiGene, Ltd. $4,414.00 01/28/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190320284
Principal investigator 1 Acerta Pharma LLC $5,331.00 01/23/2025 Non-covered Recipient Entity
TRANSLATIONAL ONCOLOGY RESEARCH INTERNATIONAL
A Randomized, Multicentre, Open-Label, Phase 3 Study to Compare Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator Choice of Chemoimmunotherapy in Subjects with Previously Untreated CLL Without del(17p) or TP53 Mutation No dispute reported 06/30/2026 1185543636
Principal investigator 1 Mirati Therapeutics, Inc. $21,185.00 01/15/2025 Non-covered Recipient Entity
Cancer Center Of Kansas
A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1236531205
Principal investigator 1 Novartis Pharmaceuticals Corporation $41,809.56 01/09/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190298339
Principal investigator 1 Genentech, Inc. $1,000.00 01/08/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 No dispute reported 06/30/2026 1211673720
Principal investigator 1 Novartis Pharmaceuticals Corporation $686,071.45 01/01/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190298316